Unknown

Dataset Information

0

Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival?

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC12337053 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape
| S-EPMC12337068 | biostudies-literature
Unknown Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
| S-EPMC6987344 | biostudies-literature
Unknown Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer.
| S-EPMC12432676 | biostudies-literature
Unknown Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer.
| S-EPMC5984716 | biostudies-literature
Unknown Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
| S-EPMC10236600 | biostudies-literature
Unknown Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
| S-EPMC7028836 | biostudies-literature
Unknown Systematic review of sequencing of ALK inhibitors in <i>ALK</i>-positive non-small-cell lung cancer.
| S-EPMC6372008 | biostudies-literature
Unknown Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.
| S-EPMC7713518 | biostudies-literature
Unknown GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.
| S-EPMC8931094 | biostudies-literature
Unknown Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
| S-EPMC10906082 | biostudies-literature